Intervention not reported
Acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide versus medroxyprogesterone: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Normal versus simulated altitude conditions: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in normal versus simulated altitude conditions: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS · participants at risk of high altitude illness
The intervention may leads to higher positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS (low certainty).
1 finding from 1 review
OR 3.67 [1.38, 9.76]
1 study · 8 participants
Low
Intervention not reported
Remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Comparisons: outcome · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Antioxidants versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in antioxidants versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Ginkgo biloba versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower ginkgo biloba versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Erythropoietin versus placebo: risk of AMS · participants at risk of high altitude illness
It is very uncertain whether the intervention changes erythropoietin versus placebo: risk of AMS (very low certainty).
1 finding from 1 review
Intervention not reported
Medroxyprogesterone versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in medroxyprogesterone versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Outcomes and intervention · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Complete relief of AMS symptoms · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Reduction in symptom score severity at 12 hours (Clinical score: ranged from 0 to 11 (worse)) Intervention: Simulated descent of 193 millibars versus 20 millibars · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
Adverse effects during treatment Intervention: Hyperbaric chamber/ 160 millibars versus supplementary oxygen · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
All‐cause mortality · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Complete relief of AMS symptoms (12 to 16 hours after treatment) Scale used: Acute Mountain Sickness score (ranged from 0 to 9 (worse)) · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
Reduction in symptom score severity Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement: Self‐administered AMS questionnaires (ranged from 0 to 90 (worse)), AMS Symptom Questionnaire (ranged from 0 to 22 (wors... · people suffering from high altitude illness
The intervention showed no clear difference in reduction in symptom score severity Time of measurement: 1 to 48… (low certainty).
1 finding from 1 review